RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

March 26, 2024

Primary Completion Date

January 1, 2025

Study Completion Date

January 31, 2026

Conditions
MigraineMigraine With AuraMigraine Without AuraChronic Migraine
Interventions
DRUG

Rimegepant 75 mg

Patients using Rimegepant 75 mg orally disintegrating tablet every other day as migraine prevention

Trial Locations (2)

27100

RECRUITING

"IRCCS National Neurological Institute C. Mondino Foundation", Pavia

50134

RECRUITING

SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi, Florence

All Listed Sponsors
collaborator

"IRCCS National Neurological Institute C. Mondino Foundation"

OTHER

collaborator

Società Italiana per lo Studio delle Cefalee

OTHER

collaborator

Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari

OTHER

collaborator

Università degli Studi dell'Aquila

OTHER

collaborator

University of Roma La Sapienza

OTHER

collaborator

Azienda Ospedaliero Universitaria Policlinico Modena

OTHER

collaborator

Ospedale di Piove di Sacco

UNKNOWN

collaborator

Azienda Ospedaliero-Universitaria di Parma

OTHER

collaborator

Azienda Ospedaliera S. Maria della Misericordia

OTHER

collaborator

A.O.U. Città della Salute e della Scienza

OTHER

collaborator

Cliniche Humanitas Gavazzeni

OTHER

collaborator

University of Campania Luigi Vanvitelli

OTHER

collaborator

Ospedale Santo Stefano

OTHER

collaborator

Azienda Policlinico Umberto I

OTHER

collaborator

Auxologico San Luca

OTHER

collaborator

Asst Degli Spedali Civili Di Brescia

OTHER

collaborator

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

OTHER

lead

University of Florence

OTHER